X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs FRESENIUS KABI ONCO. - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH FRESENIUS KABI ONCO. PANACEA BIOTECH/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 142.3 22.1 643.2% View Chart
P/BV x 3.2 3.1 101.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
FRESENIUS KABI ONCO.
Mar-13
PANACEA BIOTECH/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs149176 84.5%   
Low Rs8279 104.8%   
Sales per share (Unadj.) Rs84.137.7 223.3%  
Earnings per share (Unadj.) Rs-18.35.1 -359.4%  
Cash flow per share (Unadj.) Rs-6.76.7 -99.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.742.5 196.8%  
Shares outstanding (eoy) m61.25158.23 38.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.43.4 40.7%   
Avg P/E ratio x-6.325.0 -25.3%  
P/CF ratio (eoy) x-17.218.9 -91.1%  
Price / Book Value ratio x1.43.0 46.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,07420,135 35.1%   
No. of employees `0002.81.2 238.7%   
Total wages/salary Rs m1,449703 206.1%   
Avg. sales/employee Rs Th1,874.15,176.2 36.2%   
Avg. wages/employee Rs Th527.0610.4 86.3%   
Avg. net profit/employee Rs Th-407.7699.6 -58.3%   
INCOME DATA
Net Sales Rs m5,1545,963 86.4%  
Other income Rs m10018 554.4%   
Total revenues Rs m5,2545,981 87.8%   
Gross profit Rs m-7661,430 -53.6%  
Depreciation Rs m711258 275.7%   
Interest Rs m1,503-26 -5,780.8%   
Profit before tax Rs m-2,8811,216 -236.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-68 -2,600.4%   
Tax Rs m17342 4.9%   
Profit after tax Rs m-1,121806 -139.1%  
Gross profit margin %-14.924.0 -62.0%  
Effective tax rate %-0.628.1 -2.1%   
Net profit margin %-21.813.5 -161.0%  
BALANCE SHEET DATA
Current assets Rs m3,8105,102 74.7%   
Current liabilities Rs m8,3652,385 350.7%   
Net working cap to sales %-88.445.6 -194.0%  
Current ratio x0.52.1 21.3%  
Inventory Days Days156150 103.8%  
Debtors Days Days67113 59.3%  
Net fixed assets Rs m14,4805,148 281.3%   
Share capital Rs m61158 38.7%   
"Free" reserves Rs m9036,556 13.8%   
Net worth Rs m5,1276,732 76.2%   
Long term debt Rs m5,832952 612.4%   
Total assets Rs m19,43310,388 187.1%  
Interest coverage x-0.9-45.8 2.0%   
Debt to equity ratio x1.10.1 804.1%  
Sales to assets ratio x0.30.6 46.2%   
Return on assets %2.07.5 26.2%  
Return on equity %-21.912.0 -182.7%  
Return on capital %3.614.6 24.9%  
Exports to sales %24.574.5 32.9%   
Imports to sales %10.224.8 41.1%   
Exports (fob) Rs m1,2644,441 28.5%   
Imports (cif) Rs m5251,477 35.5%   
Fx inflow Rs m1,5395,298 29.1%   
Fx outflow Rs m9421,772 53.2%   
Net fx Rs m5973,525 16.9%   
CASH FLOW
From Operations Rs m5991,274 47.0%  
From Investments Rs m-438-1,204 36.4%  
From Financial Activity Rs m-303-196 154.3%  
Net Cashflow Rs m-141-126 111.9%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 0.6 0.3 200.0%  
FIIs % 1.3 9.6 13.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 9.1 259.3%  
Shareholders   10,259 42,599 24.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  GLENMARK PHARMA  GSK PHARMA  PLETHICO PHARMA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Sensex Touching Record Highs, Rally in Banking Stocks and Key Stocks in Action Today(Pre-Open)

BSE Sensex is on a roll. The index touched a record high of 35,000 on Wednesday and further inched upwards to end yesterday's trade at a level of 35,260.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jan 18, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS